Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
暂无分享,去创建一个
P. Laurberg | P. Caron | M. Valimaki | A. Beckers | B. Gutt | A. Picó | M. Góth | D. Cullen | W. Zgliczyński | Peter Laurberg | Albert Beckers | Antonio Picó | Matti Välimäki
[1] P. Marzullo,et al. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). , 2000, The Journal of clinical endocrinology and metabolism.
[2] P. Chanson,et al. Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: clinical implications. , 2000, European journal of endocrinology.
[3] F. Casanueva,et al. Criteria for cure of acromegaly: a consensus statement. , 2000, The Journal of clinical endocrinology and metabolism.
[4] G. Gussoni,et al. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. , 1996, The Journal of clinical endocrinology and metabolism.
[5] I. Lancranjan,et al. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. , 1995, The Journal of clinical endocrinology and metabolism.
[6] W. Young,et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. , 1995, The Journal of clinical endocrinology and metabolism.
[7] P. Caron,et al. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). , 1995, European journal of endocrinology.
[8] P. Chanson,et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. , 1994, The Journal of clinical endocrinology and metabolism.
[9] J. Kuhn,et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. , 1993, The Journal of clinical endocrinology and metabolism.
[10] M. Arosio,et al. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. , 1990, The Journal of clinical endocrinology and metabolism.
[11] A. Harris,et al. Long Term Effect of Incremental Doses of the Somatostatin Analog SMS 201–995 in 58 Acromegalic Patients* , 1990 .
[12] J. Reubi,et al. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. , 1989, The Journal of clinical endocrinology and metabolism.
[13] S. Lamberts,et al. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. , 1987, The Journal of clinical endocrinology and metabolism.
[14] I. Jackson,et al. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995). , 1986, Annals of internal medicine.
[15] H. Nawata,et al. Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients. , 1986, The Journal of clinical endocrinology and metabolism.
[16] I. Lancranjan,et al. Results of a European Multicentre Study with Sandostatin® LAR® in Acromegalic Patients , 2004, Pituitary.
[17] I. Lancranjan,et al. Sandostatin LAR in acromegalic patients: long-term treatment. , 1997, The Journal of clinical endocrinology and metabolism.
[18] P. Caron,et al. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. , 1997, The Journal of clinical endocrinology and metabolism.
[19] S. Lamberts,et al. Drug therapy : octreotide , 1996 .
[20] C. Beaudoin,et al. [Influence of dose and modalities of administration of BIM 23014 on growth hormone secretion in patients with acromegaly]. , 1992, Annales d'endocrinologie.
[21] A. Harris,et al. Long-Term Efficacy of Sandostatin®(SMS 201–995, Octreotide) in 178 Acromegalic Patients. Results from the International Multicentre Acromegaly Study Group , 1988 .